

Deferoxamine

Statut de médicament essentiel

Description générale

Deferoxamine is an iron chelating agent used in the treatment of iron overload, acute iron toxicity and in the management of sickle cell disease.

INN

Deferoxamine

Codes ATC

[V03AC01](#)

Type de médicament

Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 1979 ([TRS 641](#)) pour [Harmful effects of drugs, medicaments or biological substances, not elsewhere classified](#)

Ajouté en 2011 ([TRS 965](#)) pour [Other specified sickle cell disorders or other haemoglobinopathies](#)

Ajouté en 2023 ([TRS 1049](#)) pour [Thalassaemias](#)

Wikipédia

[Deferoxamine](#)

DrugBank

[Deferoxamine](#)

Recommandations

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Harmful effects of drugs, medicaments or biological substances, not elsewhere classified](#)

Section

Medicines for haemoglobinopathies

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias](#)